摘要
Abstract
Objective:To investigate the clinical efficacy of bevacizumab combined with CyberKnife in the treatment of patients with brain metastases.Methods:Clinical data of 86 patients with brain metastases admitted to a hospital from May 2022 to December 2023 were retrospectively selected and divided into the control group and the observation group according to different treatment regimens,with 43 patients in each group.The control group received CyberKnife treatment,while the observation group was additionally given bevacizumab injection on the basis of the control group's treatment.Immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+),peritumoral edema volume,clinical efficacy,survival status and adverse reactions were compared between the two groups.Results:After treatment,CD3+,CD4+and CD4+/CD8+in the observation group were higher than those in the control group(P<0.05),while CD8+was lower(P<0.05).Peritumoral edema volume was decreased in both groups(P<0.05),with a smaller volume in the observation group(P<0.05).The disease remission rate in the observation group(69.77%)was higher than that in the control group(46.51%,P<0.05).Both groups were followed up for 12 months,and the overall survival time in the observation group was longer than that in the control group(χ²=5.451,P=0.020).No statistically significant difference in adverse reactions was observed between the two groups(P>0.05).Conclusion:Bevacizumab combined with CyberKnife can effectively improve clinical efficacy in patients with brain metastases,reduce immune suppression and peritumoral edema,prolong survival,and does not increase the risk of adverse reactions.关键词
脑转移瘤/贝伐珠单抗/射波刀/免疫功能/生存期Key words
brain metastases/bevacizumab/CyberKnie function/immune function/survival period分类
医药卫生
